Overexpression of METTL3 associated with the metabolic status on F-FDG PET/CT in patients with Esophageal Carcinoma.

To investigate the expression of methyltransferase 3 (METTL3) and its relationship with F-FDG uptake in patients with esophageal carcinoma (ESCA). This study analyzed the expression of METTL3 in ESCA and its relationship with clinicopathological features by The Cancer Genome Atlas (TCGA) database. Immunohistochemical staining was performed on 57 tumor tissues of ESCA patients who underwent PET/CT scan before surgery to evaluate the expression of METTL3, glucose transporter 1 (GLUT1), and hexokinase 2 (HK2) in tumor tissues and peritumoral tissues. Analyze the relationship between SUVmax with METTL3, HK2, and GLUT1 expression. The expression of METTL3, GLUT1, and HK2 was significantly increased in ESCA tissues compared with normal tissues ( 0.001). The expression of METTL3 was correlated with tumor size and histological differentiation ( 0.05), and there was no significant difference between age, sex, pathological types, tumor staging, or lymph node metastasis ( > 0.05). The SUVmax was significantly higher in tumors with high METTL3 expression (17.822±6.249) compared to low METTL3 expression (9.573±5.082) ( 0.001). There was a positive correlation between the SUVmax and METTL3 expression in ESCA ( = 0.647, 0.001). Multivariate analysis confirmed the association between SUVmax and METTL3 expression ( 0.05). GLUT1 and HK2 expression in ESCA was positively correlated with F-FDG uptake and METTL3 status ( 0.001). The high expression of METTL3 is related to the high SUVmax in ESCA, and METTL3 may increase F-FDG uptake by regulating GLUT1 and HK2.